Cypris Therapeutics Launches as Newest Ichor Life Sciences Portfolio Company, Secures Over $500k in Pre-Seed Funding
June 24 2024 - 3:34PM
Business Wire
Cypris Therapeutics, a drug discovery company, has launched
following a breakthrough in synthetic chemistry technology which
allows development of novel chemistries for treatment of
therapeutically resistant diseases, including brain and pancreatic
cancers.
"At Cypris Therapeutics, we are driven by a mission to develop
life-saving therapies for some of the deadliest and therapeutically
challenging diseases," said Kyle Parella, PhD, Co-Founder and CEO
at Cypris. "Our technology represents a new frontier in cancer
treatment, offering hope to patients who currently have limited
options."
The company's proprietary technology enables the synthesis and
iteration of complex small molecule moieties that have been
previously unattainable by researchers. The molecules are inspired
by those found in nature with demonstrated therapeutic properties.
Cypris can modify these natural molecules to improve their
therapeutic properties and reduce undesired side effects. This
synthetic chemistry innovation holds the potential to significantly
improve the standard of care for patients that do not respond to
existing treatments.
Cypris Therapeutics has formed as the newest start-up in the
portfolio of Ichor Life Sciences, a Syracuse-based contract
research organization. Ichor is leading Cypris’s pre-seed funding
round, which has already garnered over $500,000. Cypris will
incubate at Ichor's facilities and gain access to Ichor’s
state-of-the-art equipment in addition to drug discovery and
development expertise.
Ichor CEO and Founder Kelsey Moody, PhD, MBA stated, "We see
vast potential in Cypris Therapeutics’ technology not only as a
promising opportunity to develop next generation oncology
treatments, but as a platform for iterating natural products for
other age-related indications where traditional medicinal chemistry
approaches have been elusive.”
Cypris Therapeutics remains committed to its vision of
delivering innovative cancer treatments that make a real difference
in patients' lives. As the company moves forward, it continues to
seek additional funding and partnerships to support its ambitious
goals.
For more information or media inquiries about Cypris
Therapeutics, contact info@cypristx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240624611665/en/
info@cypristx.com